Business
Notice of Results
Notice of Results.
About this update from Futura Medical Plc
[{"type":"text","content":"\n\n19 August 2024\n \nFutura Medical plc\n(\"Futura\" or the \"Company\")\nNotice of Results\nFutura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, will announce its unaudited results for the six months ended 30 June 2024 on Tuesday 10 September 2024.\n \nThe Company will be hosting a webinar for retail investors via the Investor Meet Company platform on 10 September 2024, at 9:00am BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9:00am BST the day before, or at any time during the live presentation.\n \nInvestors can register for the presentation via the following link: https://www.investormeetcompany.com/futura-medical-plc/register-investor\n \nIn addition, management will be hosting a webinar for analysts on 10 September 2024 at 11:00am BST. If you would like to register, please contact [email protected]\n \n \nContacts:\n\n\n\n\nFutura Medical plc\n \n \n \n\n\nJames Barder\nChief Executive Officer\nAngela Hildreth\nFinance Director and COO\n \n\n\[email protected]\n+44 (0)1483 685 670\nwww.futuramedical.com\n \n\n\n\n\nPanmure Liberum\nNominated Adviser\nand Broker\n \n\n\nEmma Earl, Will Goode, Mark Rogers (Corporate Finance)\nRupert Dearden (Corporate Broking)\n\n\n+44 (0)20 3100 2000\n \n \n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nStifel Nicolaus Europe Limited\nJoint Broker\n \n\n\nAlan Selby\nBen Maddison\n \n\n\n+44 (0)207 710 7600\n \n \n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nAlma Strategic Communications\n\n\nRebecca Sanders-Hewett\nSam Modlin\nWill Ellis Hancock\n\n\n+44 (0)20 3405 0205\[email protected]\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nNotes to Editors:\nFutura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.\nEroxon, Futura's clinically proven lead product, has been developed for the treatment of Erectile Dysfunction ...